Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07607600 · ClinicalTrials.gov registry record
Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia
A clinical trial, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- 100
- Enrollment target
NCT07607600 is a clinical trial that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 100 participants.
The verdict
NCT07607600 has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking burosumab and how they relate to bone health, overall disease burden and XLH-related conditions.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07-07 |
| Est. Completion | 2030-07-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07607600
The ClinicalTrials.gov registry entry for NCT07607600 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT07607600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07607600 about?
NCT07607600 is a clinical study titled "Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia". The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking burosumab and how they relate to bone health, overall disease burden and XL...
What is the current status of trial NCT07607600?
This trial is currently not yet recruiting. The enrollment target is 100 participants. The study started on 2026-07-07. Estimated completion is 2030-07-07.
What interventions are being tested in trial NCT07607600?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT07607600?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.